About Inimmune
Inimmune is a Healthcare company based in Missoula (United States) founded in 2016 by Kendal Ryter. Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders. Inimmune has raised $22 million across 3 funding rounds from investors including NIH, HHS and Two Bear Capital. The company has 35 employees. Inimmune offers products and services including INI-2004, INI-4001, and TRAC478. Its focus areas include Life Sciences, Immunotherapy, Diversified and Infectious Diseases. Its legal entity is INIMMUNE CORP. Its competitors include BeiGene, TScan Therapeutics and Vir Biotechnology; 3 of its 3 listed competitors have raised funding.
Company details
Inimmune was founded in 2016 in Missoula, United States, within the biotechnology sector. Focus is placed on discovering and developing innate immune receptor agonists and antagonists to address food allergies, allergic rhinitis, and autoimmune disorders. The pipeline encompasses preclinical vaccines for food allergies, modulators for rhinitis, and discovery-stage TLR antagonists for Th1Th2Th17-mediated conditions. Fee-based contract services, including drug formulation, analytical chemistry, immunology, and chemical synthesis, are offered to pharmaceutical partners.
- Headquarters Missoula, United States
- Employees 35
- Founders Kendal Ryter
- SectorsHealthcare
- Website inimmune.com
- Social LinkedIn X Facebook
- Legal Name Inimmune Corp.
- Total Equity Funding$22M (USD)
in 3 rounds
- Latest Funding Round$22M (USD), Series A
Jul 2020
- InvestorsNIH
& 2 more
- Employee Count35
Products & Services of Inimmune
Inimmune offers a comprehensive portfolio of products and services, including INI-2004, INI-4001, and TRAC478.
TLR4 agonist for treating allergic rhinitis in clinical trials
TLR7/8 agonist for cancer treatment with checkpoint inhibitors
Adjuvant system for enhancing vaccine responses
Funding Insights of Inimmune
Inimmune has successfully raised a total of $22M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22M
- Total Rounds 3
- Last Round Series A — $22M
- First Round $1.19M
(Feb 2018)
- Investors Count 3
All 3 funding rounds of Inimmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $22M | Series A | – | Two Bear Capital | – |
| Jul 2020 | $2M | Grant | – | – | |
| Feb 2018 | $1.19M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Inimmune
Inimmune has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Two Bear Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Two Bear Capital is focused on investing in innovative founders. | 2019 | twobearcapital.com | Whitefish, Montana, USA | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Inimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inimmune
16 people are tracked at Inimmune (8 in leadership, 1 in board & advisors, 7 in team); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Kendal Ryter | Co-Founder & VP Product Development | Leadership |
Helene Bazin Lee | Co-founder & Vice President | Leadership |
David Burkhart | Co-founder & Chief Operating Officer | Leadership |
Jon Ruckle | Chief Medical Officer | Leadership |
Mike Sullivan | Chief Financial Officer | Leadership |
Jay T. Evans | Chief Scientific & Strategy Officer | Leadership |
Juhienah Khalaf | Director of Chemistry | Leadership |
Evans Jay | Chief Scientific and Strategy Officer | Leadership |
Michael Goguen | Director | Board & advisors |
Rebekah Tee | Associate Scientist | Team |
Marie Snyder | HR and Administrative Lead | Team |
Uddav Pandey | Senior Scientist | Team |
Eric Ward | Formulations Development Manager | Team |
Robert Child | Manager, Business Operations and Finance | Team |
Ahmad Junaid | Senior Scientist | Team |
Van Cybulski | Senior Scientist | Team |
Complete people profiles for Inimmune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Inimmune
3 dated milestones of Inimmune across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Inimmune is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Series A, of $22.0M.
Competitors of Inimmune
Inimmune has 3 listed competitors in our database, 3 of them funded. They include BeiGene, TScan Therapeutics and Vir Biotechnology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases |
Detailed competitors of Inimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Inimmune
The website of Inimmune (inimmune.com) receives about 3.8K visits a month.
- Monthly visits3.8K
▲ 18.7% vs previous month
Websites whose visitors overlap most with Inimmune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
saasconnect.in | saasconnect.in | 100% | – | ||
| albasmelter.com | 99% | 17.6K | #1,489,703 | View details | |
| nmg.com | 86% | 26.8K | #856,796 | View details |
Top companies in Oncology
3 companies that operate in the same segment as Inimmune (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inimmune
Complete news archive for Inimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inimmune
Inimmune was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Inimmune is headquartered in Missoula, United States. It is registered at Missoula, Montana, United States.
Inimmune is a funded company, having raised a total of $22M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.19M, raised on Feb 2018.
Inimmune has 35 employees.
Inimmune was founded in 2016 in Missoula, United States, within the biotechnology sector. Focus is placed on discovering and developing innate immune receptor agonists and antagonists to address food allergies, allergic rhinitis, and autoimmune disorders. The pipeline encompasses preclinical vaccines for food allergies, modulators for rhinitis, and discovery-stage TLR antagonists for Th1Th2Th17-mediated conditions. Fee-based contract services, including drug formulation, analytical chemistry, immunology, and chemical synthesis, are offered to pharmaceutical partners.
Inimmune's top competitors include BeiGene, TScan Therapeutics and Vir Biotechnology.
Inimmune offers INI-2004, INI-4001, and TRAC478.
Inimmune has 3 investors. Key investors include NIH, HHS, and Two Bear Capital.
Inimmune operates through Inimmune Corp..